NCT00411632View on ClinicalTrials.gov

BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 29, 2006

Primary Completion Date

February 23, 2018

Study Completion Date

February 23, 2018

Conditions
Lung Cancer
Interventions
DRUG

Bexarotene

400 mg/m\^2 by mouth daily x 28 Days

DRUG

Erlotinib

150 mg by mouth daily x 28 Days

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER

NCT00411632 - BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter